These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22589397)

  • 1. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.
    Vitale LA; He LZ; Thomas LJ; Widger J; Weidlick J; Crocker A; O'Neill T; Storey J; Glennie MJ; Grote DM; Ansell SM; Marsh H; Keler T
    Clin Cancer Res; 2012 Jul; 18(14):3812-21. PubMed ID: 22589397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.
    He LZ; Prostak N; Thomas LJ; Vitale L; Weidlick J; Crocker A; Pilsmaker CD; Round SM; Tutt A; Glennie MJ; Marsh H; Keler T
    J Immunol; 2013 Oct; 191(8):4174-83. PubMed ID: 24026078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
    Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
    J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
    Guelen L; Fischmann TO; Wong J; Mauze S; Guadagnoli M; Bąbała N; Wagenaars J; Juan V; Rosen D; Prosise W; Habraken M; Lodewijks I; Gu D; Stammen-Vogelzangs J; Yu Y; Baker J; Lutje Hulsik D; Driessen-Engels L; Malashock D; Kreijtz J; Bertens A; de Vries E; Bovens A; Bramer A; Zhang Y; Wnek R; Troth S; Chartash E; Dobrenkov K; Sadekova S; van Elsas A; Cheung JK; Fayadat-Dilman L; Borst J; Beebe AM; Van Eenennaam H
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
    French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
    Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
    Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
    Vitale LA; He LZ; Thomas LJ; Wasiuk A; O'Neill T; Widger J; Crocker A; Mills-Chen L; Forsberg E; Weidlick J; Patterson C; Hammond RA; Boyer J; Sisson C; Alvarado D; Goldstein J; Marsh HC; Keler T
    Cancer Immunol Immunother; 2020 Oct; 69(10):2125-2137. PubMed ID: 32451681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of CD27 in complex with a neutralizing noncompeting antibody.
    Teplyakov A; Obmolova G; Malia TJ; Gilliland GL
    Acta Crystallogr F Struct Biol Commun; 2017 May; 73(Pt 5):294-299. PubMed ID: 28471362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the human CD27 ligand, a novel member of the TNF gene family.
    Hintzen RQ; Lens SM; Beckmann MP; Goodwin RG; Lynch D; van Lier RA
    J Immunol; 1994 Feb; 152(4):1762-73. PubMed ID: 8120385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
    Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
    Silence K; Dreier T; Moshir M; Ulrichts P; Gabriels SM; Saunders M; Wajant H; Brouckaert P; Huyghe L; Van Hauwermeiren T; Thibault A; De Haard HJ
    MAbs; 2014; 6(2):523-32. PubMed ID: 24492296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
    Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
    Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.
    Wei SM; Fei JX; Tao F; Pan HL; Shen Q; Wang L; Wu YJ; Zhou L; Zhu SX; Liao WB; Ji H; Xin ZL
    Int Surg; 2015 Jan; 100(1):155-63. PubMed ID: 25594656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
    Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
    Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontline Science: Late CD27 stimulation promotes IL-7Rα transcriptional re-expression and memory T cell qualities in effector CD8
    Dong H; Buckner A; Prince J; Bullock T
    J Leukoc Biol; 2019 Nov; 106(5):1007-1019. PubMed ID: 31199542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.
    Sakanishi T; Yagita H
    Biochem Biophys Res Commun; 2010 Mar; 393(4):829-35. PubMed ID: 20171165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
    Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
    Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.